Revance Therapeutics (RVNC)
(Delayed Data from NSDQ)
$3.40 USD
+0.11 (3.34%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.41 +0.01 (0.29%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Income Statements
Fiscal Year end for Revance Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 234 | 133 | 78 | 15 | 0 |
Cost Of Goods | 74 | 52 | 23 | 5 | 0 |
Gross Profit | 160 | 81 | 54 | 11 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 476 | 423 | 329 | 284 | 165 |
Income After Depreciation & Amortization | -317 | -342 | -275 | -273 | -164 |
Non-Operating Income | 12 | 3 | 0 | 4 | 5 |
Interest Expense | 19 | 16 | 6 | 15 | 0 |
Pretax Income | -324 | -356 | -281 | -285 | -159 |
Income Taxes | 0 | 1 | 0 | -3 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -324 | -356 | -281 | -282 | -159 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -324 | -356 | -281 | -282 | -159 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -214 | -303 | -253 | -254 | -164 |
Depreciation & Amortization (Cash Flow) | 103 | 39 | 21 | 20 | 0 |
Income After Depreciation & Amortization | -317 | -342 | -275 | -273 | -164 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 84.60 | 72.71 | 67.51 | 58.01 | 43.46 |
Diluted EPS Before Non-Recurring Items | -3.83 | -4.90 | -4.17 | -4.86 | -3.67 |
Diluted Net EPS (GAAP) | -3.83 | -4.90 | -4.17 | -4.86 | -3.67 |
Fiscal Year end for Revance Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 69.80 | 56.78 | 58.13 | 49.33 |
Cost Of Goods | NA | 17.47 | 19.41 | 21.31 | 16.17 |
Gross Profit | NA | 52.33 | 37.36 | 36.83 | 33.16 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 29.11 | 176.65 | 102.33 | 91.19 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 23.22 | -139.29 | -65.50 | -58.03 |
Non-Operating Income | NA | 3.65 | 3.51 | 2.55 | 2.74 |
Interest Expense | NA | 5.40 | 5.09 | 4.37 | 4.50 |
Pretax Income | NA | -55.70 | -140.88 | -67.32 | -59.79 |
Income Taxes | NA | 0.00 | 0.30 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -55.70 | -141.18 | -67.32 | -59.79 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -55.70 | -141.18 | -67.32 | -59.79 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 90.15 | 86.61 | 83.69 | 81.13 |
Diluted EPS Before Non-Recurring Items | NA | -0.62 | -0.74 | -0.80 | -0.74 |
Diluted Net EPS (GAAP) | NA | -0.66 | -1.63 | -0.80 | -0.74 |